Performance of the Abbott RealTime MTB RIF/INH resistance assay when used to test Mycobacterium tuberculosis specimens from Bangladesh

Infection and Drug Resistance, May 2018

Performance of the Abbott RealTime MTB RIF/INH resistance assay when used to test Mycobacterium tuberculosis specimens from Bangladesh Joshua Kostera, Gregor Leckie, Klara Abravaya, Hong Wang Abbott Molecular, Abbott Laboratories, Des Plaines, IL, USA Introduction: The Abbott RealTime MTB RIF/INH Resistance Assay (RT MTB RIF/INH) is an assay for the detection of rifampicin (RIF)- and/or isoniazid (INH)-resistant Mycobacterium tuberculosis (MTB). The assay can be used to test sputum, bronchial alveolar lavage, and N-Acetyl-L-Cysteine (NALC)/NaOH pellets prepared from these samples. The assay can be used in direct testing mode, or in reflex mode following a MTB positive result produced by its companion assay, Abbott RT MTB. Methods: In this study, the direct testing mode was used to test paired sputum and NALC/NaOH pellets prepared from sputum collected from Bangladesh TB patients. One hundred and thirty two paired samples were tested. Results: The RT MTB RIF/INH inhibition rate was 0%. One hundred and twenty-two paired samples had results above the assay limit of detection and were analyzed by comparing with results from phenotypic drug sensitivity testing, GeneXpert MTB/RIF (Xpert), and MTBDR plus (Hain). RT MTB RIF/INH results were in good agreement with those of GeneXpert and Hain. Conclusion: The ability of this assay to detect RIF and INH resistance may contribute to the global control of multidrug resistant tuberculosis. Keywords: tuberculosis, rifampicin, isoniazid, resistance

A PDF file should load here. If you do not see its contents the file may be temporarily unavailable at the journal website or you do not have a PDF plug-in installed and enabled in your browser.

Alternatively, you can download the file locally and open with any standalone PDF reader:

https://www.dovepress.com/getfile.php?fileID=42043

Performance of the Abbott RealTime MTB RIF/INH resistance assay when used to test Mycobacterium tuberculosis specimens from Bangladesh

Infection and Drug Resistance Performance of the Abbott RealTime MTB RIF/INH resistance assay when used to test Mycobacterium tuberculosis specimens from Bangladesh 0 Abbott Molecular , Abbott Laboratories, Des Plaines, IL , USA PowerdbyTCPDF(ww.tcpdf.org) Introduction: The Abbott RealTime MTB RIF/INH Resistance Assay (RT MTB RIF/INH) is an assay for the detection of rifampicin (RIF)- and/or isoniazid (INH)-resistant Mycobacterium tuberculosis (MTB). The assay can be used to test sputum, bronchial alveolar lavage, and N-Acetyl-L-Cysteine (NALC)/NaOH pellets prepared from these samples. The assay can be used in direct testing mode, or in reflex mode following a MTB positive result produced by its companion assay, Abbott RT MTB. Methods: In this study, the direct testing mode was used to test paired sputum and NALC/ NaOH pellets prepared from sputum collected from Bangladesh TB patients. One hundred and thirty two paired samples were tested. Results: The RT MTB RIF/INH inhibition rate was 0%. One hundred and twenty-two paired samples had results above the assay limit of detection and were analyzed by comparing with results from phenotypic drug sensitivity testing, GeneXpert MTB/RIF (Xpert), and MTBDR plus (Hain). RT MTB RIF/INH results were in good agreement with those of GeneXpert and Hain. Conclusion: The ability of this assay to detect RIF and INH resistance may contribute to the global control of multidrug resistant tuberculosis. Introduction Mycobacterium tuberculosis (MTB) remains a significant disease with 10.4 million new cases of tuberculosis (TB) reported in 2015.1 Anti-TB therapy is effective in at least 85% of cases when the causative strain of MTB is sensitive to the four drugs (rifampicin [RIF], isoniazid [INH], ethambutol, and pyrazinamide) that constitute frontline therapy.1 Treatment with front-line therapy is less effective when MTB is resistant to one or more of these drugs.1 It is therefore important to detect MTB resistance to one or more of these front-line drugs so that therapy can be modified appropriately.1 Detection of drug-resistant MTB is often performed using the accurate but slow (up to 12 weeks) culture-based (phenotypic) drug sensitivity testing (DST).1 In response to the relative length of time to generate a phenotypic DST result, more rapid nucleic acid amplification tests (NAAT) have been developed.2 The Cepheid GeneXpert MTB/RIF (Xpert) assay detects mutations associated with RIF resistance while Hain MTBDR Plus (Hain) detects mutations associated with RIF and INH resistance.3–6 Abbott RealTime MTB RIF/INH Resistance (RT MTB RIF/INH) detects mutations associated with resistance to RIF and INH.7 RT MTB RIF/INH is a companion assay to Abbott RealTime MTB (RT MTB).8,9 It can be used in direct testing mode to test Infection and Drug Resistance 2018:11 695–699 695 © 2018 Kostera et al. This work is published and licensed by Dove Medical Press Limited. The ful terms of this license are available at https://www.dovepress.com/terms. php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). 8 1 0 2 l u J 2 1 n o 7 0 2 . 6 4 . 9 5 . 7 3 y b / m o c . s s e r respiratory specimens (sputum, bronchial alveolar lavage, or N-Acetyl-L-Cysteine (NALC)/NaOH sediments prepared from sputum or bronchial alveolar lavage) or used in reflex mode following a positive RT MTB result.7 The performance of RT MTB RIF/INH has been studied in in Germany, Hong Kong, and South Africa in reflex mode, following an RT MTB positive result.10–12 The intent of this study was to review the performance of RT MTB RIF/INH when used in direct testing mode with MTB culture-positive samples from Bangladesh for which phenotypic DST, Xpert, and Hain results had been generated. The inclusion of DST, as well as Xpert and MTBDR plus results for this patient population provides a measure of performance for RT MTB RIF/INH against phenotypic DST and Xpert and Hain assays. Methods Samples .vdoepww l.syoeun sTuhsrpeeecstepdutoufmhsapveincigmaecntsivweeTreB.coSlpleecctiemdefnrsomwe1r3e2csoullbejcetcetds /sw lna under the supervision of the National TB Reference Lab / : ttp rso h e Institutional Review Board and Intercenter Agreement. All p from roF subjects enrolled in this study provided written informed ded consent. The three sputum specimens were collected from loan each patient over a maximum period of 5 days, with at least dow 5 hours between collections. Collection was performed at the cen National Reference Laboratory in Dhaka, Bangladesh. Speciitssa mens were collected following Institutional Review B (...truncated)


This is a preview of a remote PDF: https://www.dovepress.com/getfile.php?fileID=42043

Joshua Kostera, Gregor Leckie, Klara Abravaya, Hong Wang. Performance of the Abbott RealTime MTB RIF/INH resistance assay when used to test Mycobacterium tuberculosis specimens from Bangladesh, Infection and Drug Resistance, 2018, pp. 695-699, DOI: 10.2147/IDR.S158953